Myocardial Infarction, Acute Clinical Trial
Official title:
Study of Acute and Chronic Myocardiac Lesions Angiogenesis by 68Ga-NODAGA-RGD Cardiac PET
The study is about exploring physiological angiogenesis linked to tissue repair in patients with acute heart infarction or chronic heart ischemia by means of 68Ga-NODAGA-RGD PET/CT imaging.
Several animal studies have demonstrated the expression of αvβ3 integrins on the surface of the endothelium present in neovessels in formation, especially during neoangiogenesis after myocardial ischemic injury. 68Ga-NODAGA-RGD is a positron-emission-tomography (PET) ligand targeted towards αvβ3 integrins. αvβ3 integrins could potentially act as a biomarker for the follow-up of heart infarction. In the present study, 68Ga-NODAGA-RGD PET/CT imaging is a tool to understand and evaluate tissue repair after heart lesion and its evolution allowing a better management of patients with occluded artery. Three groups of patients are included : patients with acute infarction, patients with acute infarction requiring reperfusion treatment and patients with chronic ischemic occlusion. Each patient would benefit from a 82Rb (82rubidium) PET/CT as part of standard management and from a 68Ga-NODAGA-RGD PET/CT as part of the present study. Patients from groups 1 and 2 will have 3 sets of both exams : one after the ischemic event, one at one month and another at 3 months post event. Patients form group 3 will have a set of both exams before reperfusion treatment and one at 2 months after reperfusion. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05759078 -
Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion
|
Phase 4 | |
Completed |
NCT06408636 -
Prognostic Role of LA Strain in Acute Myocardial Infarction
|
||
Recruiting |
NCT06038994 -
Prognostic Value of Surem TRAF3IP2 Level in Patients With Acute Myocardial Infarction
|
||
Recruiting |
NCT04968808 -
Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI)
|
N/A | |
Completed |
NCT03338504 -
Determining the Mechanism of Myocardial Injury and Role of Coronary Disease in Type 2 Myocardial Infarction
|
||
Recruiting |
NCT03317691 -
The ALERT-Pilot Study
|
N/A | |
Active, not recruiting |
NCT05077683 -
Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF
|
Phase 3 | |
Recruiting |
NCT03957005 -
Cardiovascular Risk Assessment Model in Patients With MI
|
||
Enrolling by invitation |
NCT05955950 -
Gratitude Intervention in Promoting Self-care in Patients With Myocardial Infarction
|
N/A | |
Active, not recruiting |
NCT06141252 -
Benefit of Hypothermia in OHCA Complicating AMI
|
N/A | |
Not yet recruiting |
NCT04560023 -
Effectiveness of Multimedia Exposure in Patients Transferred to Hospital Suffering From Acute Myocardial Infarction
|
N/A | |
Recruiting |
NCT06430892 -
RAPID-POP a Randomized Controlled Trial
|
N/A | |
Completed |
NCT05118009 -
Artificial Intelligence Based Rapid Identification of ST-elevation Myocardial Infarction Using Electrocardiogram (ARISE)
|
N/A | |
Active, not recruiting |
NCT04753749 -
Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy
|
N/A | |
Completed |
NCT04769219 -
Secondary Prevention Education After Acute Myocardial Infarction
|
N/A | |
Active, not recruiting |
NCT05350969 -
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
|
Phase 2 | |
Recruiting |
NCT05999110 -
Algarve Active Ageing - Cardiac and Osteoarthritis Rehabilitation (A3-COR)
|
N/A | |
Completed |
NCT04167904 -
Biomarkers in Patients Hospitalized With Suspected Acute Myocardial Infarction
|
||
Not yet recruiting |
NCT04989777 -
IABP In AMI Patients With SCAI-B Study
|
N/A | |
Recruiting |
NCT05043610 -
MSCs for Prevention of MI-induced HF
|
Phase 3 |